Canaccord analyst William Plovanic lowered the firm's price target on Ceribell to $25 from $28 and keeps a Buy rating on the shares. The firm said Ceribell posted another operationally solid quarter in Q1 with a beat and raise where the guidance was raised by more than the beat and management gave helpful granularity on new rep productivity.
